Cediranib: Difference between revisions
Content deleted Content added
No edit summary |
Carlo Banez (talk | contribs) - to shorten size of SVG structure |
||
Line 2: | Line 2: | ||
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-<br>7-[3-(pyrrolidin-1-yl)propoxy]quinazoline |
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-<br>7-[3-(pyrrolidin-1-yl)propoxy]quinazoline |
||
| image = AZD2171.svg |
| image = AZD2171.svg |
||
| width = 250px |
|||
| CAS_number = |
| CAS_number = |
||
| ATC_prefix = |
| ATC_prefix = |
Revision as of 18:17, 25 March 2008
Clinical data | |
---|---|
Routes of administration | Oral |
Pharmacokinetic data | |
Elimination half-life | 12 to 35 hours |
Identifiers | |
| |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.196.628 |
Chemical and physical data | |
Formula | C25H27FN4O3 |
Molar mass | 450.5 g/mol g·mol−1 |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.
As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.
On February 27th in 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
Further reading
- Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link)